agilon health, inc.

---

source: coverage-next-full ticker: AGL company: agilon health, inc. step: 01 title: Business Model & Overview created: 2026-06-04

Step 01 — Business Model & Overview: agilon health, inc. (AGL)

1. Company Summary

agilon health, inc. (NYSE: AGL) is a value-based care (VBC) enablement company that partners with independent primary care physician (PCP) groups to manage Medicare Advantage (MA) beneficiaries under a full-risk, global capitation model. Rather than owning clinics or employing physicians, agilon provides a platform — including payer contracting infrastructure, technology analytics, care management programs, and operational support — that allows existing community physicians to bear and benefit from full MA risk. [S1][S2]

Elevator pitch: agilon transforms fee-for-service community primary care physicians into capitated Medicare Advantage partners, keeping patients healthy and capturing the gap between capitation premiums and actual medical costs as "medical margin."

2. Value Chain Layer Map

Medicare Advantage Plans (Humana, UHC, BCBS, Aetna, etc.)
    │
    │  Per-member-per-month (PMPM) capitation payments
    ▼
agilon health Platform
    │  • Global capitation contracts with MA plans
    │  • Technology platform (analytics, risk-adjustment coding support)
    │  • Care management programs (high-risk patient identification)
    │  • Operational support (billing, quality, payer relations)
    │  • Shared financial risk structure with physician groups
    ▼
Physician Partner Groups (~30 independent groups, 12 states)
    │  • Primary care physician panels take on full financial risk
    │  • Revenue = capitation PMPM × covered members
    │  • Medical margin = capitation revenue − total medical costs
    ▼
Patients (Medicare Advantage beneficiaries, ~511K covered lives, FY2025)

Revenue flow: MA plans pay agilon's physician partner entities a fixed PMPM capitation for each enrolled member. agilon recognizes this full capitation as its revenue. Medical costs (hospitalizations, specialist care, pharmacy, etc.) are subtracted to calculate Medical Margin — the economic "gross profit" of the business. agilon receives a platform fee from the physician group's net economics; the physician group retains operating income after agilon's fee. [S2]

3. Business Model Components

3a. Risk-Based Enablement (RBE) Structure

Component	Description
Entity type	agilon-backed physician group legal entity (RBE)
Payer contracts	Global capitation directly from MA plans
Physician relationship	Independent physicians contracted with the RBE
agilon's role	Platform provider + risk/reward participant
Capital deployment	agilon funds initial losses while groups scale to positive medical margin

The RBE structure allows agilon to consolidate full capitation revenue while keeping physicians autonomous — a critical differentiator vs. employed-physician models (Oak Street Health, ChenMed) and fee-for-service enablement models (Privia Health). [S8]

3b. Revenue Mechanics

• Revenue = Capitation PMPM × Total MA Members × 12 months
• PMPM rates are set annually by CMS through the MA bidding process, then negotiated between the MA plan and agilon's RBE
• Revenue risk-adjustment: capitation is adjusted for member acuity (HCC risk scores); risk-adjustment true-ups have been a material negative item in FY2024 and FY2025
• Part D (prescription drug) is included in capitation — a new and material cost driver following the Inflation Reduction Act changes effective 2024

3c. Medical Margin (Economic Gross Profit)

Capitation Revenue
  − Total Medical Costs (hospitalizations, specialists, pharmacy, Part D)
= Medical Margin

Medical Margin %  =  Medical Margin / Revenue

FY	Revenue	Medical Margin	MM%
2021	$1,443M	$134M	9.3%
2022	$3,307M	$164M	5.0%
2023	$4,800M	$299M	6.2%
2024	$6,059M	$205M	3.4%
2025	$5,922M	($57M)	(1.0%)

[S1][S2]

4. Geographic & Partnership Footprint

Metric	FY2025	FY2024
States	12	13
Geographies	~28	~30
Physician partner groups	~29	~30
MA covered members	~511K	~526K

Strategy: agilon exited underperforming markets (notably Hawaii and California in FY2023) and continues rationalizing partnerships. FY2026 guidance assumes members shrink to ~430K as additional underperforming markets/contracts exit. [S2][S6]

5. Revenue Concentration

agilon's top MA plan partners are not individually disclosed, but Humana, UnitedHealth Group, Aetna (CVS), and BCBS affiliates collectively represent the majority of capitation revenue. Single-plan concentration risk is moderated by multi-payer contracting in most markets, but MA plan consolidation is a monitoring item. [S2]

6. Competitive Positioning

Model Type	Example	Key Difference vs. AGL
Employed physician VBC	Oak Street Health (CVS), ChenMed	AGL doesn't own clinics; physicians remain independent
Non-risk enablement	Privia Health	Privia is fee-for-service focused; AGL takes full capitation risk
Risk-bearing IPAs	SCAN, CareMore	Health-plan-owned; AGL is independent platform
Self-managed VBC	WellMed (UHC)	Captive physician networks; AGL physicians are community-based

Key moat claim: Physician stickiness — once a physician group takes capitation risk via agilon's platform, switching costs are high (rebuilt payer relationships, analytics dependencies, working capital support). [S8]

7. Source Index

ID	Source
S1	SEC EDGAR XBRL — AGL company facts
S2	AGL 10-K FY2024
S6	AGL_financials/other/business_deep_research.md
S8	AGL_financials/industry/competitive_landscape.md

---

source: coverage-next-full ticker: AGL company: agilon health, inc. step: 04 title: Financial Quality & Adversarial Sweep created: 2026-06-04

Step 04 — Financial Quality: agilon health, inc. (AGL)

1. Income Statement Quality Assessment

Revenue Recognition

• Revenue recognized on a gross basis (full capitation PMPM × members) per ASC 606
• Capitation revenue is monthly, straight-line; no material timing distortions
• Risk-adjustment settlements are estimated and trued up quarterly; FY2024 and FY2025 saw material adverse true-ups ($37M and $48M respectively) — this is NOT a recognition distortion, it reflects the genuine actuarial uncertainty in CMS risk-adjustment methodology [S2]
• Quality: CLEAN on recognition method; elevated estimation risk on risk-adjustment true-ups is disclosed prominently

Medical Cost Accruals

• agilon records IBNR (Incurred But Not Reported) claims liability based on actuarial estimates
• IBNR balance: FY2024 $~460M → FY2025 $~502M
• Reserve development (adverse vs. favorable) has been a persistent negative in FY2024–FY2025
• Quality: WATCH — IBNR adequacy is the most critical financial reporting risk; management has a track record of underestimating medical costs in recent years

Non-GAAP Adjustments

• Adjusted EBITDA excludes: SBC ($50–55M/yr), D&A ($35M/yr), restructuring charges (~$15M in FY2025), legal/investigation costs
• SBC is large relative to the company's scale (~$50M on a ~$5.9B revenue base but very large relative to the ~-$57M medical margin in FY2025)
• Quality: MODERATE CONCERN — Adjusted EBITDA in FY2025 ($-230M) is much better than GAAP loss ($-356M); the adjustments are standard but SBC is not trivial

2. Balance Sheet Quality

Metric	FY2024	FY2025	Assessment
Cash & equivalents	$259M	$182M	Declining rapidly; key liquidity monitor
Total debt	$50M	$50M	Minimal; $50M revolving credit facility (undrawn as of Q1 2026)
Goodwill + intangibles	~$125M	~$120M	Legacy; modest impairment risk
Claims payable (IBNR)	~$460M	~$502M	Largest liability; actuarial risk embedded
Total equity	~$378M	~$22M	Nearly depleted by cumulative losses

Capital structure note: AGL is effectively equity-funded with minimal traditional debt. However, the claims payable (IBNR) represents a contingent liability that could require cash payment materially in excess of estimates if adverse development continues. The equity base is nearly zero; another year of FY2025-magnitude losses would require external capital. The FY2026 turnaround is therefore existentially important. [S1][S2]

Reverse stock split (March 31, 2026, 1:25): Executed to maintain NYSE listing compliance — the stock had fallen below the $1.00 minimum bid price. This is a material signal of the severity of the FY2025 crisis, not just cosmetic. [S6]

3. Cash Flow Quality

Metric	FY2023	FY2024	FY2025
Operating Cash Flow	($80M)	($57M)	($187M)
Capex	($16M)	($21M)	($18M)
Free Cash Flow	($96M)	($78M)	($205M)

FY2025 FCF of -$205M represents the worst cash burn year. Management guided FY2026 cash burn to dramatically narrow given EBITDA inflection. [S1]

Working capital note: Capitation payments are received monthly in advance; medical costs are paid with a lag. This creates a structural working capital benefit in growth phases but can reverse during membership declines as run-out claims must still be paid on departing members.

4. SBC Analysis

Year	SBC	SBC / Revenue	SBC / Medical Margin
FY2022	$64M	1.9%	39%
FY2023	$59M	1.2%	20%
FY2024	$55M	0.9%	27%
FY2025	$50M	0.8%	N/M (negative MM)

SBC as % of revenue is low, but as % of medical margin it is extremely high in FY2024–2025. SBC is a significant cost to equity holders even if excluded from Adj. EBITDA. [S1]

5. Adversarial Research Sweep

5a. Securities Class Action (Active)

Filed: December 31, 2025 Class period: February 2, 2024 – August 4, 2025 Allegations: The complaint alleges AGL misled investors about the sustainability of its medical margin and the severity of deteriorating medical cost trends during the class period. Specifically, plaintiffs allege AGL knew or should have known that: (1) Medicare Advantage medical costs were trending significantly above estimates; (2) risk-adjustment true-ups would be materially adverse; (3) Part D IRA changes would materially impair profitability — and failed to timely disclose this risk. The CEO departure on August 4, 2025 (simultaneous with guidance suspension) serves as the alleged "corrective disclosure" event.

Assessment: The allegations are legally plausible — the abruptness of the FY2025 guidance suspension and CEO departure is facially unusual. However, AGL's core defense is that medical cost deterioration in MA was industry-wide (HUM, CVS, ELV all experienced elevated MA costs in 2024–2025) and was not predictable with certainty. Securities class actions in healthcare frequently settle; material cash outflow is possible but the timeframe is typically 2–4 years. [S6]

5b. Short Seller History

No major organized short-seller campaign against AGL was identified. Short interest peaked pre-reverse-split at ~26.7M equivalent shares (~6% of post-split float equivalent) and had substantially compressed by May 2026 to ~640K shares (0.8 days to cover). The compression occurred as FY2026 early results recovered. No SEC investigation publicly disclosed as of research date. [S5]

5c. Accounting Red Flags Assessment

Risk Area	Finding	Severity
IBNR reserve adequacy	Consistent adverse development FY2024–2025; this is genuine actuarial uncertainty, not manipulation evidence	MEDIUM
SBC exclusion from Adj. EBITDA	Standard practice; disclosed; but large relative to economics	LOW-MEDIUM
Gross revenue recognition	Per ASC 606; appropriate for the RBE structure	LOW
Related party transactions	No material related-party transactions identified	LOW
Audit firm	Deloitte (large national firm)	LOW
Going concern	Not disclosed in FY2025 10-K; balance sheet stressed but management believes FY2026 guidance provides sufficient liquidity	LOW-MEDIUM

5d. Management Credibility Events

Event	Date	Implication
CEO Steven Sell resignation	Aug 4, 2025	Simultaneous with guidance suspension — raises credibility questions about FY2024–2025 disclosures
Guidance suspension Aug 2025	Aug 4, 2025	Only the second time in company history guidance was suspended
FY2025 medical margin -$57M vs. original guidance of +$175M+	Dec 2025	~$232M guidance miss — material
Reverse stock split	Mar 2026	Avoided delisting; signal of severity
New CEO O'Rourke joined	May 2026	VBC veteran; credibility upgrade vs. crisis period

Net credibility assessment: The prior management team's credibility is compromised by the FY2025 earnings miss severity. New CEO O'Rourke's first full guidance cycle (FY2026) will be a critical test. Q1 2026 beat ($149M medical margin vs. ~$120M implied guidance) is a positive first data point. [S6]

6. Key Financial Quality Adjustments for Modeling

1. IBNR adequacy: Add 5–10% IBNR development risk haircut to medical margin estimates in scenarios
2. SBC: Treat as real economic cost in bear/base case analysis (reduces true profitability by ~$50M/yr)
3. Reverse split adjustment: All per-share historical data post-split is retroactively adjusted (÷25); verify all per-share figures from databases use the adjusted basis
4. Part D tail: FY2026 contracts explicitly reprice Part D; the risk should diminish, but one more year of adverse development is a monitoring item

7. Source Index

ID	Source
S1	SEC EDGAR XBRL — AGL company facts
S2	AGL 10-K FY2024
S5	Analyst consensus data
S6	AGL_financials/other/business_deep_research.md

---

source: coverage-next-full ticker: AGL company: agilon health, inc. step: 12 title: Bull vs. Bear Analyst Debate created: 2026-06-04

Step 12 — Bull vs. Bear: agilon health, inc. (AGL)

Note: Transcripts not loaded. Bull/bear debate constructed from analyst consensus notes, broker research summaries, press release commentary, and news sources (coverage-next-full path).

1. Current Market Context

As of research date (2026-06-04):

• Stock price: ~$82.70 (post 1:25 reverse split; pre-split equivalent ~$3.31)
• Market cap: ~$1.38B
• Enterprise value: ~$1.30B
• Analyst mean price target: ~$58–60 (well below current price)
• Consensus: ~"Hold"
• Street distribution: roughly 3–5 Buy, 8–10 Hold, 2–3 Sell

The setup is unusual: AGL stock has rallied >2.5× from its post-guidance-suspension lows on Q1 2026 beat, and the stock now trades ABOVE the analyst mean target. This creates a bifurcated debate between momentum bulls (the turnaround is proving out) and fundamental skeptics (the ROIC story is still unproven; membership is shrinking; litigation overhang). [S5]

2. Bull Case Thesis

Argument B1: Q1 2026 MCR Proves the Turnaround is Real

Claim: Q1 2026 MCR of ~88% is not a seasonal artifact — it reflects AGL's portfolio rationalization working. The company exited ~85K members (net) in Q1 2026; those were the highest-MCR, most problematic markets. The remaining 426K members represent a quality book that sustainably generates $25–30/member/month medical margin.

Evidence: $149M medical margin in Q1 2026 on 426K members; EPS $1.80 vs. $0.93 consensus; FY2026 guidance raised post-Q1.

Bull price target: $90–95 (Benchmark target cited). Basis: 0.3× EV/Revenue (FY2026E $5.7B revenue) = $1.7B EV → ~$100/share. Or: 10× FY2027E Adj. EBITDA of ~$175M = ~$1.75B EV.

Argument B2: FY2026 Is the First Year of a Multi-Year Earnings Recovery

Claim: Adj. EBITDA is going from -$230M (FY2025) to +$20M (FY2026E) to potentially +$150–200M (FY2027E). This is a meaningful earnings trajectory that will attract multiple expansion as the company moves from "distressed turnaround" to "recovering growth" framing.

Evidence: Q1 2026 adj. EBITDA ~$55M annualizes to $220M — well above FY2026 guidance of $15–25M. Management explicitly guided to positive FY2026 adj. EBITDA for the first time in company history.

Argument B3: FY2026 MA Rate Increase (+7.2%) Is the Most Favorable in Years

Claim: The combination of AGL's contract resets (which include explicit Part D repricing) and the largest CMS base rate increase in years creates a macro tailwind that the FY2024–2025 cohort did not enjoy.

Evidence: CMS finalized FY2026 rate announcement at +7.2% effective base rate change; combined with contract resets, PMPM rates for remaining AGL markets should be materially higher in 2026 than 2025.

3. Bear Case Thesis

Argument B1: Q1 Is the Seasonally Best Quarter — Q2–Q4 Will Reveal the True Run-Rate

Claim: Q1 is always the best MCR quarter in Medicare Advantage because utilization (hospitalizations, procedures) is seasonally lowest in January–March. The Q1 2026 MCR of ~88% cannot be annualized; Q2–Q4 historically run 3–5 percentage points higher. FY2026 guidance of $15–25M adj. EBITDA (implying full-year medical margin ~$375M) requires Q2–Q4 to hold at MCR ~93–94%. That's far from guaranteed given recent medical cost trend experience.

Evidence: AGL's own recent history: Q1 2024 MCR 93.9% vs. full-year FY2024 MCR 96.6%; Q1 2023 MCR ~91% vs. full-year 93.8%. The seasonal pattern is real and meaningful.

Bear price target: $21 (JPMorgan cited). Basis: Discounted to ~0.3× book value + option value on turnaround.

Argument B2: Membership Contraction Limits Revenue Recovery Even If MCR Normalizes

Claim: AGL is guiding to ~430K members at FY2026 year-end — 18% below the FY2025 peak. Revenue will be ~$5.7B in FY2026 and $5.5–5.8B in FY2027 even in a recovery scenario. This is a business whose top line is shrinking, not growing. At the current stock price ($82 post-split), the market is pricing in a revenue recovery that requires new partnership additions the company has not yet committed to.

Evidence: FY2026 guidance implies flat-to-declining members; FY2027 new partner additions would require 2–3 year ramp periods to add meaningful revenue; revenue decline from peak unlikely to reverse until FY2028+.

Argument B3: Securities Litigation + Balance Sheet Fragility Create Asymmetric Downside Risk

Claim: The securities class action (class period Feb 2024–Aug 2025; filed Dec 2025) could result in a $50–200M settlement that materially impacts the cash balance ($182M FY2025). At the guided ~$125M FY2026 year-end cash, a $100M settlement payment would leave AGL below minimum operating liquidity, potentially requiring a dilutive equity raise at an inopportune time.

Evidence: AGL acknowledged the lawsuit in its FY2025 10-K. Class period aligns with a $250M+ guidance miss. Similarly-sized MA misstatement cases have settled at $40–150M range.

4. Analyst Debate Summary

Dimension	Bull	Bear
Q1 2026 MCR ~88%	Structural improvement; portfolio exit working	Seasonal; Q2–Q4 will revert to ~93–96%
Membership decline to 430K	Right-sizing; remaining book high quality	Revenue ceiling effect; growth requires 2–3yr ramp
FY2026 guidance $15–25M EBITDA	Floor, not ceiling; Q1 beat implies upside	Seasonality means Q2–Q4 could disappoint
Legal/cash risk	Will settle for modest amount; cash sufficient	Could force dilutive raise; litigation tail is long
New CEO O'Rourke	VBC veteran; Q1 beat is his first data point	Only 1 month in office as of Q1 report; unproven

5. Bull Case — 3 Bullets

• Q1 2026 MCR of ~88% demonstrates portfolio rationalization is working: Exiting ~85K underperforming members dramatically improved the remaining book's economics, and FY2026 contract resets explicitly price in Part D and risk-adjustment realities for the first time — creating a structurally cleaner earnings base.
• First guided positive EBITDA year (FY2026 $15–25M) marks an inflection that should command multiple expansion: As AGL transitions from "cash-burning turnaround" to "EBITDA-positive platform company," it should re-rate from deep distress multiples toward healthcare services comps (5–10× EBITDA), which implies meaningful upside from current levels if guidance holds.
• +7.2% CMS MA base rate in FY2026 provides the largest external PMPM tailwind in company history: Combined with AGL's contract resets, this creates an asymmetric setup where even modest MCR normalization produces outsized medical margin — the bull case is that Q2–Q4 2026 remain more favorable than historical seasonality suggests, driven by the MA rate increase absorbing the residual V28 headwind.

6. Bear Case — 3 Bullets

• Q1 is the seasonally best Medicare Advantage quarter; the ~88% MCR is not the sustainable run-rate: Q2–Q4 historically run 3–5 percentage points above Q1 on MCR; if FY2026 full-year MCR averages 95%+ (as in FY2024), the $375M guided medical margin collapses to near-zero, and the securities class action + balance sheet fragility could force a dilutive equity raise.
• Membership is planned to shrink to 430K in FY2026 (vs. 526K peak) and recovery requires 2–3 year physician group ramp: Revenue will be structurally below $6B through at least FY2028, and the current ~$1.38B market cap implies >15× EV/FY2026 EBITDA — a premium multiple for a still-recovering, litigation-laden company with a largely unproven new CEO.
• Securities class action creates $50–200M tail liability at precisely the moment when cash is thin (~$125M guided FY2026 year-end): Any settlement or adverse legal development in FY2026–2027 could exhaust liquidity and trigger a dilutive capital raise, re-testing the stock near its prior crisis lows.

7. Source Index

ID	Source
S2	AGL 10-K FY2024
S5	Analyst consensus and broker targets
S6	AGL_financials/other/business_deep_research.md